Carlsmed saw significant gains in fourth-quarter and 2025 revenue, according to financial results posted Feb. 25.
Five things to know:
1. Full-year revenue was $50.5 million, an 86% increase from 2024. Fourth quarter revenue grew 61% with $15.2 million.
2. Gross profits in 2025 grew to $38 million compared to $20 million in 2024. However the company operated on a $29.6 net loss in 2025.
3. Highlights of the fourth quarter included the launch of the aprevo cervical system and the myaprevo ecosystem for browser and mobile integration. The company also saw the first in-human bi-lateral posterior fusion and corra cervical plating cases.
4. The company expects 2026 revenue to reach $70 million to $75 million.
5. “These achievements demonstrate our momentum and the speed at which we are scaling while maintaining our culture of patient-centric innovation,” Mike Cordonnier, chair and CEO, said in the release. “With recent published data from a patient-matched cohort showing a 74% reduction in revision rates at two years for aprevo lumbar patients versus non-aprevo patients, we continue to advance our mission of improved outcomes and reduced cost of healthcare with a highly differentiated approach.”
